BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3323707)

  • 21. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
    Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
    Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simulators of malignant melanoma of the skin.
    Cerroni L; Kerl H
    Eur J Dermatol; 1998 Sep; 8(6):388-96. PubMed ID: 9729049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of monoclonal antibody 225.28S in the study of nevus cells in culture].
    Raffaelli M; Fimiani M; Castelli A; Mancianti ML; Valentino A; Andreassi L
    Boll Soc Ital Biol Sper; 1984 Mar; 60(3):467-71. PubMed ID: 6370274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphometry of melanocytic skin lesions--verifications or vexations? A review of a group experience.
    Williams RA
    Pathologica; 1998 Apr; 90(2):183-5. PubMed ID: 9619064
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple congenital melanocytic naevi presenting with neurofibroma-like lesions complicated by malignant melanoma.
    Gach JE; Carr RA; Charles-Holmes R; Harris S
    Clin Exp Dermatol; 2004 Sep; 29(5):473-6. PubMed ID: 15347327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immuno-diagnosis of malignant melanoma].
    Szekeres G; Battyáni Z
    Magy Onkol; 2003; 47(1):45-50. PubMed ID: 12704454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline and atypical melanocytic lesions.
    Brodell RT; Santa Cruz DJ
    Semin Diagn Pathol; 1985 Feb; 2(1):63-86. PubMed ID: 3916688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathological characteristics of malignant melanoma affecting mucous membranes: a unifying concept of histogenesis.
    Saida T; Kawachi S; Takata M; Kurita H; Kurashina K; Kageshita T; Tonogi M; Okazaki Y; Yamane GY; Takubo K; Ueyama Y
    Pathology; 2004 Oct; 36(5):404-13. PubMed ID: 15370109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The dermatoscope. A simplification of epiluminescent microscopy of pigmented skin changes].
    Braun-Falco O; Stolz W; Bilek P; Merkle T; Landthaler M
    Hautarzt; 1990 Mar; 41(3):131-6. PubMed ID: 2345096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Triggered trap": nevoid malignant melanoma.
    McNutt NS
    Semin Diagn Pathol; 1998 Aug; 15(3):203-9. PubMed ID: 9711670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Step-wise expression of melanoma-associated antigens in tumor progression].
    Lehmann JM; Holzmann B; Rothbächer U; Riethmüller G; Johnson JP
    Onkologie; 1989 Dec; 12(6):273-6. PubMed ID: 2696911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Improving clinical diagnosis of pigmented skin changes in childhood with the dermatoscope].
    Stolz W; Bilek P; Merkle T; Landthaler M; Braun-Falco O
    Monatsschr Kinderheilkd; 1991 Feb; 139(2):110-3. PubMed ID: 2038348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.
    Gown AM; Vogel AM; Hoak D; Gough F; McNutt MA
    Am J Pathol; 1986 May; 123(2):195-203. PubMed ID: 3518473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epidermotropic and junctional metastases of malignant melanoma].
    Meunier L; Beauvais L; Costes Y; Barnéon G; Pages A; Meynadier J
    Ann Dermatol Venereol; 1988; 115(12):1279-80. PubMed ID: 3242411
    [No Abstract]   [Full Text] [Related]  

  • 36. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi.
    Ruiter DJ; Dingjan GM; Steijlen PM; van Beveren-Hooyer M; de Graaff-Reitsma C; Bergman W; van Muijen GN; Warnaar SO
    J Invest Dermatol; 1985 Jul; 85(1):4-8. PubMed ID: 3891875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 receptor expression in benign and malignant melanocytic skin lesions.
    Kernohan NM; Sewell HF
    J Pathol; 1989 Apr; 157(4):315-9. PubMed ID: 2785590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
    Takahashi H; Strutton GM; Parsons PG
    Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanocytes express 3G5 surface antigen.
    Fiedler E; Nayak RC; Marsch WCh; Helmbold P
    Am J Dermatopathol; 2004 Jun; 26(3):200-4. PubMed ID: 15166506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cutaneous melanoma mimicking nevus].
    Bailly C; Prade M; Dolbeau D
    Ann Pathol; 1992; 12(4-5):216-22. PubMed ID: 1466675
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.